Skip to content

NovoCure NVCR Enterprise value

Enterprise value at other companies

Boston Scientific logo
Boston ScientificBSX
$141.04B-1.0%
Medtronic logo
MedtronicMDT
$131.22B-3.2%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$1.3B+33.2%
Nuvation Bio logo
Nuvation BioNUVB
$1.42B+154%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$1.24B+102%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$958.05M+65.4%

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.64B-36.7%
P/S2.4×-1.7×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's enterprise value?
NovoCure (NVCR) reported enterprise value of $1.19B in Q1 2026.
How has NovoCure's enterprise value changed year-over-year?
NovoCure's enterprise value decreased by 36.3% year-over-year, from $1.87B to $1.19B.
What is the long-term trend for NovoCure's enterprise value?
Over 5 years (2020 to 2025), NovoCure's enterprise value has grown at a -40.1% compound annual growth rate (CAGR), from $18.18B to $1.41B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.